Arvinas reports preclinical combo data for PROTAC BCL6 degrader ARV-393 with complete regressions in lymphoma

ARVINAS, INC.

ARV-393 plus R-CHOP induced complete tumor regressions in all mice, outperforming single agents alone.
Combination with SOC biologics (rituximab, tafasitamab, polatuzumab vedotin) resulted in tumor regressions in DLBCL models.
ARV-393 increased CD20 expression in preclinical models, supporting combinations with CD20-targeted agents.
Combination with investigational SMIs (acalabrutinib, venetoclax, tazemetostat) showed superior growth inhibition with regressions.
Phase 1 study for ARV-393 (NCT06393738) enrolling patients with relapsed/refractory non-Hodgkin lymphoma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.